Get started
Author

Elisa Zanini

Observed names: E Zanini, E. Zanini, Zanini, Elisa
ORCID: 0000-0002-5659-1626
Observed ORCID: 0000-0002-5659-1626
OpenAlex ID: A5038779465
Oxidative metabolism drives inflammation-induced platinum resistance in human ovarian cancer
2016 · D S Matassa, M R Amoroso, et al. · Cell Death and Differentiation · 199
PDF
The OPCML Tumor Suppressor Functions as a Cell Surface Repressor–Adaptor, Negatively Regulating Receptor Tyrosine Kinases in Epithelial Ovarian Cancer
2012 · Arthur B. McKie, Sebastian Vaughan, et al. · Cancer Discovery · 52
The tumour suppressor OPCML promotes AXL inactivation by the phosphatase PTPRG in ovarian cancer
2018 · Jane Antony, Elisa Zanini, et al. · EMBO Reports · 38
WWOX sensitises ovarian cancer cells to paclitaxel via modulation of the ER stress response
2017 · Szymon Janczar, Jaya Nautiyal, et al. · Cell Death and Disease · 32
PDF
The Tumor-Suppressor Protein OPCML Potentiates Anti–EGFR- and Anti–HER2-Targeted Therapy in HER2-Positive Ovarian and Breast Cancer
2017 · Elisa Zanini, Louay S. Louis, et al. · Molecular Cancer Therapeutics · 27
PDF
Emerging roles for the GPI-anchored tumor suppressor OPCML in cancers
2020 · Jane Antony, Elisa Zanini, et al. · Cancer Gene Therapy · 15
Inactivating mutations and X-ray crystal structure of the tumor suppressor OPCML reveal cancer-associated functions
2019 · James R. Birtley, Mohammad Alomary, et al. · Nature Communications · 14
PDF
Dual TTK/PLK1 inhibition has potent anticancer activity in TNBC as monotherapy and in combination
2024 · Elisa Zanini, Nicole Forster-Gross, et al. · Frontiers in Oncology · 10
PDF
Abstract 5645: BAL0891: A novel dual TTK/PLK1 mitotic checkpoint inhibitor (MCI) that drives aberrant tumor cell division resulting in potent anti-cancer activity
2022 · Heidi A. Lane, Felix Bachmann, et al. · Cancer Research · 5
Derazantinib, a fibroblast growth factor receptor inhibitor, inhibits colony-stimulating factor receptor-1 in macrophages and tumor cells and in combination with a murine programmed cell death ligand-1-antibody activates the immune environment of murine syngeneic tumor models
2022 · Mahmoud El Shemerly, Elisa Zanini, et al. · Anti-Cancer Drugs · 3
Abstract 5501: Derazantinib, an FGFR1-3 inhibitor, inhibits CSF1R in macrophages and tumor cell lines, and synergizes with a PDL1-antibody in an FGFR-driven murine syngeneic model
2022 · Mahmoud EL Shemerly, Laurenz Kellenberger, et al. · Cancer Research · 3
42P BAL0891: A novel, small molecule, dual TTK/PLK1 mitotic checkpoint inhibitor (MCI) with potent single agent activity
2022 · H.A. Lane, E. Zanini, et al. · Annals of Oncology · 2
Figure S1 from The Tumor-Suppressor Protein OPCML Potentiates Anti–EGFR- and Anti–HER2-Targeted Therapy in HER2-Positive Ovarian and Breast Cancer
2023 · Elisa Zanini, Louay S. Louis, et al.
Figure S5 from The Tumor-Suppressor Protein OPCML Potentiates Anti–EGFR- and Anti–HER2-Targeted Therapy in HER2-Positive Ovarian and Breast Cancer
2023 · Elisa Zanini, Louay S. Louis, et al.
Legends from The Tumor-Suppressor Protein OPCML Potentiates Anti–EGFR- and Anti–HER2-Targeted Therapy in HER2-Positive Ovarian and Breast Cancer
2023 · Elisa Zanini, Louay S. Louis, et al.
Figure S6 from The Tumor-Suppressor Protein OPCML Potentiates Anti–EGFR- and Anti–HER2-Targeted Therapy in HER2-Positive Ovarian and Breast Cancer
2023 · Elisa Zanini, Louay S. Louis, et al.
Figure S3 from The Tumor-Suppressor Protein OPCML Potentiates Anti–EGFR- and Anti–HER2-Targeted Therapy in HER2-Positive Ovarian and Breast Cancer
2023 · Elisa Zanini, Louay S. Louis, et al.
Figure S2 from The Tumor-Suppressor Protein OPCML Potentiates Anti–EGFR- and Anti–HER2-Targeted Therapy in HER2-Positive Ovarian and Breast Cancer
2023 · Elisa Zanini, Louay S. Louis, et al.
Figure S4 from The Tumor-Suppressor Protein OPCML Potentiates Anti–EGFR- and Anti–HER2-Targeted Therapy in HER2-Positive Ovarian and Breast Cancer
2023 · Elisa Zanini, Louay S. Louis, et al.
Data from The Tumor-Suppressor Protein OPCML Potentiates Anti–EGFR- and Anti–HER2-Targeted Therapy in HER2-Positive Ovarian and Breast Cancer
2023 · Elisa Zanini, Louay S. Louis, et al.
Legends from The Tumor-Suppressor Protein OPCML Potentiates Anti–EGFR- and Anti–HER2-Targeted Therapy in HER2-Positive Ovarian and Breast Cancer
2023 · Elisa Zanini, Louay S. Louis, et al.
Figure S3 from The Tumor-Suppressor Protein OPCML Potentiates Anti–EGFR- and Anti–HER2-Targeted Therapy in HER2-Positive Ovarian and Breast Cancer
2023 · Elisa Zanini, Louay S. Louis, et al.
Figure S6 from The Tumor-Suppressor Protein OPCML Potentiates Anti–EGFR- and Anti–HER2-Targeted Therapy in HER2-Positive Ovarian and Breast Cancer
2023 · Elisa Zanini, Louay S. Louis, et al.
Figure S2 from The Tumor-Suppressor Protein OPCML Potentiates Anti–EGFR- and Anti–HER2-Targeted Therapy in HER2-Positive Ovarian and Breast Cancer
2023 · Elisa Zanini, Louay S. Louis, et al.
Figure S5 from The Tumor-Suppressor Protein OPCML Potentiates Anti–EGFR- and Anti–HER2-Targeted Therapy in HER2-Positive Ovarian and Breast Cancer
2023 · Elisa Zanini, Louay S. Louis, et al.
Works count: 57
Citation count: 400
H-index: 8
I10-index: 8
Year
Topic
Type